EVOLUTION OF EPILEPSY ASSOCIATED WITH COVID-19 IN A TERTIARY PRIVATE HOSPITAL IN NORTHERN MEXICO AFTER THREE YEARS OF THE PANDEMIC

Main Article Content

Sofía Lucila Rodríguez Rivera José Antonio Infante Cantú Héctor R. Martínez Enrique Caro Osorio

Abstract

Background: Apart from new-onset seizures due to acute illness, the impact of COVID-19 on patients with pre-existing epilepsy has been immense.


Aims: To study patients after three years of the COVID-19 pandemic in order to assess the prevalence of new-onset seizures resulting from COVID-19 infections, the prevalence of seizure exacerbations in people with epilepsy, and the evolution of epilepsy.


Methods: A descriptive, prospective, observational, and longitudinal study. Inclusion criteria were patients with epilepsy as a presenting symptom of COVID-19 confirmed with Polymerase Chain Reaction (PCR) for SARS-CoV2 by nasopharyngeal swab from March 2020-July 2021 in a tertiary private hospital. Study variables were age, gender, type, and evolution of epilepsy. It was classified into three groups: acute symptomatic seizures, the onset of epilepsy, and uncontrolled epilepsy. Information was captured in Excel and analyzed in SPSS.


Results: Of 203,987 patients with a confirmed diagnosis of COVID-19 in Nuevo León until July 2021, 10 patients (0.004%) were included with seizures. Two patients had acute symptomatic seizures (20%), four patients had new-onset seizures (40%) and four patients (40%) had uncontrolled epilepsy with an average epilepsy evolution time of 15.75 years.  Focal seizures were predominant in 63%. After three years of the COVID-19 pandemic in 2023, 75% of patients continued with uncontrolled epilepsy with the use of the antiseizure drug.


Conclusion: Our study shows that there is evidence of the susceptibility of people with COVID-19 to present acute symptomatic seizures, new-onset seizures, and uncontrolled epilepsy, with an unfavorable course of epilepsy continuing with uncontrolled seizures and use of anti-seizure drugs, which agrees with what is reported in the literature.

Keywords: seizures, epilepsy, COVID-19, SARS-CoV-2

Article Details

How to Cite
RODRÍGUEZ RIVERA, Sofía Lucila et al. EVOLUTION OF EPILEPSY ASSOCIATED WITH COVID-19 IN A TERTIARY PRIVATE HOSPITAL IN NORTHERN MEXICO AFTER THREE YEARS OF THE PANDEMIC. Medical Research Archives, [S.l.], v. 11, n. 5, may 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3855>. Date accessed: 03 oct. 2024. doi: https://doi.org/10.18103/mra.v11i5.3855.
Section
Research Articles

References

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.

2. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;413:116832.

3. Asadi-Pooya AA. Seizures associated with coronavirus infections. Seizure. 2020;79:49–52.

4. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci. 2018;12:386.

5. Asadi-Pooya AA, Attar A, Moghadami M, Karimzadeh I (2020) Management of COVID-19 in people with epilepsy: drug considerations. Neurol Sci:1–7.

6. Qin C., Zhou L., Hu Z., Yang S., Zhang S., Chen M., Yu H., Tian D.-S., Wang W. Clinical characteristics and outcomes of COVID-19 patients with a history of stroke in Wuhan, China. MedRxiv. 2020.

7. Benussi A., Pilotto A., Premi E., Libri I., Giunta M., Agosti C., Alberici A., Baldelli E., Benini M., Bonacina S., Brambilla L., Caratozzolo S., Cortinovis M., Costa A., Piccinelli S.C., Cottini E., Cristillo V., Delrio I., Filosto M., Gamba M., Gazzina S., Gilberti N., Gipponi S., Imarisio A., Invernizzi P., Leggio U., Leonardi M., Liberini P., Locatelli M., Masciocchi S., Poli L., Rao R., Risi B., Rozzini L., Scalvini A., Schiano di Cola F., Spezi R., Vergani V., Volonghi I., Zoppi N., Borroni B., Magoni M., Pezzini A., Padovani A. Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. MedRxiv. 2020.

8. Antonini A., Leta V., Teo J., Chaudhuri K.R. Outcome of parkinson’s disease patients affected by COVID-19. Mov. Dis Bianchetti A., Rozzini R., Guerini F., Boffelli S., Ranieri P., Minelli G., Bianchetti L., Trabucchi M. Clinical presentation of COVID19 in dementia Patients. J. Nutr. Health Aging. 2020:1–3.ord. 2020;2019.

9. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P.A., Clarke M., Devereaux P.J., Kleijnen J., Moher D. 2009. The PRISMA Statement for Reporting Systematic Reviews and Meta-analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration.

10. Asadi-Pooya AA, Simani L, Shahisavandi M, Barzegar Z. COVID-19, de novo seizures, and epilepsy: a systematic review. Neurol Sci. 2021 Feb;42(2):415-431.

11. Narula N, Joseph R, Katyal N, et al. Seizure and COVID-19: Association and review of potential mechanism. Neurol Psychiatry Brain Res. 2020;38:49-53.

12. Anand P, Al-Faraj A, Sader E, Dashkoff J, Abdennadher M, Murugesan R, et al. Seizure as the presenting symptom of COVID-19: a retrospective case series. Epilepsy Behav. 2020;112:107335.

13. Bhatta S, Sayed A, Ranabhat B, Bhatta RK, Acharya Y. New-onset seizure as the only presentation in a child with COVID-19. Cureus. 2020;12:e8820.

14. Farley M, Zuberi J. COVID-19 precipitating status epilepticus in a pediatric patient. Am J Case Rep. 2020;21:e925776.

15. Shawkat A, Merrell ET, Fadel GA, Amzuta I, Amin H, Shah AJ, et al. Multiple thrombotic events in a 67-year-old man 2 weeks after testing positive for SARS-CoV-2: a case report. Am J Case Rep. 2020;21:e925786.

16. Lyons S, O’Kelly B, Woods S, Rowan C, Brady D, Sheehan G, et al. Seizure with CSF lymphocytosis as a presenting feature of COVID-19 in an otherwise healthy young man. Seizure. 2020;80:113–114.

17. Elgamasy S, Kamel MG, Ghozy S, Khalil A, Morra ME, Islam SMS (2020) First case of focal epilepsy associated with SARS-coronavirus-2. J Med Virol. 10.1002/jmv.26113.

18. Kadono Y, Nakamura Y, Ogawa Y, Yamamoto S, Kajikawa R, Nakajima Y, Matsumoto M, Kishima H. A case of COVID-19 infection presenting with a seizure following severe brain edema. Seizure. 2020;80:53–55.

19. Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, dela Cruz C, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Barakat LA. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurol. 2020;20:248.

20. Kabashneh S, Ali H, Alkassis S. Multi-organ failure in a patient with diabetes due to COVID-19 with clear lungs. Cureus. 2020;12:e8147.

21. Bergey GK. Management of a first seizure. Continuum (Minneap Minn) 2016;22(1 Epilepsy):38–50.

22. French JA, Brodie MJ, Caraballo R, Devinsky O, Ding D, Jehi L, Jette N, Kanner A, Modi AC, Newton CR, Patel AA, Pennell PB, Perucca E, Sander JW, Scheffer IE, Singh G, Williams E, Wilmshurst J, Cross JH. Keeping people with epilepsy safe during the COVID-19 pandemic. Neurology. 2020;94:1032–1037.

23. Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: A systematic review. Clin Neurol Neurosurg. 2021 Jan;200:106349.

24. Lai SL, Hsu MT, Chen SS. The impact of SARS on epilepsy: the experience of drug withdrawal in epileptic patients. Seizure. 2005;14:557–561.

25. Asadi-Pooya AA, Emami A, Akbari A, Javanmardi F. COVID-19 presentations and outcome in patients with epilepsy. Acta Neurol Scand. 2021 Jun;143(6):624-628.

26. Lu L., Xiong W., Liu D., Liu J., Yang D., Li N., Mu J., Guo J., Li W., Wang G., Gao H., Zhang Y., Lin M., Chen L., Shen S., Zhang H., Sander J.W., Luo J., Chen S., Zhou D. New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: a retrospective multicenter study. Epilepsia. 2020.

27. Zheng K.S., Dorfman B.J., Christos P.J., Khadem N.R., Henchcliffe C., Piboolnurak P., Nirenberg M.J. Clinical characteristics of exacerbations in parkinson disease. Neurologist. 2012;18:120–124.

28. Cunningham C. Systemic inflammation and delirium: important co-factors in the progression of dementia. Biochem. Soc. Trans. 2011;39:945–953.

29. Xu J., Zhong S., Liu J., Li L., Li Y., Wu X., Li Z., Deng P., Zhang J., Zhong N., Ding Y., Jiang Y. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. Am. 2005;41:1089–1096.

30. Assenza G, Lanzone J, Brigo F, Coppola A, Di Gennaro G, Di Lazzaro V, et al. Epilepsy care in the time of COVID-19 pandemic in Italy: risk factors for seizure worsening. Front Neurol. 2020;11:737.